(Q37778379)

23 August 2017

1 reference

title

Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions (English)

1 reference

23 August 2017

0 references

André J Scheen

1

1 reference

23 August 2017

publication date

1 September 2010

1 reference

Clinical Pharmacokinetics

23 August 2017

published in

1 reference

23 August 2017

volume

49

1 reference

23 August 2017

issue

9

1 reference

23 August 2017

page(s)

573-588

1 reference

https://scigraph.springernature.com/pub.10.2165/11532980-000000000-00000

23 August 2017

exact match

0 references

cites work

New combination treatments in the management of diabetes: focus on sitagliptin-metformin

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F11532980-000000000-00000

Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F11532980-000000000-00000

Pharmacokinetics of alogliptin when administered with food, metformin, or cimetidine: a two-phase, crossover study in healthy subjects

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F11532980-000000000-00000

Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies

21 January 2018

1 reference

12 December 2020

Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects

1 reference

12 December 2020

1 reference

12 December 2020

Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes

1 reference

12 December 2020

Sitagliptin: a review of its use in the management of type 2 diabetes mellitus

1 reference

12 December 2020

Effect of the novel oral dipeptidyl peptidase IV inhibitor vildagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.

1 reference

12 December 2020

Vildagliptin in clinical practice: a review of literature.

1 reference

12 December 2020

Current management strategies for coexisting diabetes mellitus and obesity

1 reference

12 December 2020

The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone

1 reference

12 December 2020

Multiple doses of sitagliptin, a selective DPP-4 inhibitor, do not meaningfully alter pharmacokinetics and pharmacodynamics of warfarin

1 reference

12 December 2020

Effect of a single cyclosporine dose on the single-dose pharmacokinetics of sitagliptin (MK-0431), a dipeptidyl peptidase-4 inhibitor, in healthy male subjects

1 reference

12 December 2020

Angiotensin-converting enzyme and dipeptidyl peptidase IV inhibitors: an increased risk of angioedema.

1 reference

12 December 2020

Renal failure and rhabdomyolysis associated with sitagliptin and simvastatin use. But what about the amiodarone?

1 reference

12 December 2020

Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study.

1 reference

12 December 2020

DPP4 inhibitors: from sitagliptin monotherapy to the new alogliptin-pioglitazone combination therapy

1 reference

12 December 2020

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

1 reference

12 December 2020

Oral Antidiabetic Agents

1 reference

12 December 2020

Combination treatment in the management of type 2 diabetes: focus on vildagliptin and metformin as a single tablet

1 reference

12 December 2020

Evaluation of pharmacokinetic interactions between vildagliptin and digoxin in healthy volunteers

1 reference

12 December 2020

Vildagliptin: a review of its use in the management of type 2 diabetes mellitus.

1 reference

12 December 2020

Dipeptidyl peptidase-IV inhibitors: a major new class of oral antidiabetic drug

1 reference

12 December 2020

The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion.

1 reference

12 December 2020

Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors

1 reference

12 December 2020

Renal failure and rhabdomyolysis associated with sitagliptin and simvastatin use.

1 reference

12 December 2020

Saxagliptin: a new dipeptidyl peptidase 4 inhibitor for type 2 diabetes.

1 reference

12 December 2020

Evaluation of pharmacokinetic and pharmacodynamic interaction between the dipeptidyl peptidase IV inhibitor vildagliptin, glyburide and pioglitazone in patients with Type 2 diabetes.

1 reference

12 December 2020

Coadministration of pioglitazone or glyburide and alogliptin: pharmacokinetic drug interaction assessment in healthy participants.

1 reference

12 December 2020

Drug evaluation: vildagliptin-metformin single-tablet combination.

1 reference

12 December 2020

Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone

1 reference

12 December 2020

Oral antidiabetic agents. A guide to selection

1 reference

12 December 2020

Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus

1 reference

12 December 2020

Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

12 December 2020

Cytochrome P450 drug interactions within the HMG-CoA reductase inhibitor class: are they clinically relevant?

1 reference

12 December 2020

Addition of incretin therapy to metformin in type 2 diabetes

1 reference

12 December 2020

Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)

1 reference

12 December 2020

Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study

1 reference

12 December 2020

Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin--diabetes control and potential adverse events

1 reference

12 December 2020

Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes

1 reference

12 December 2020

Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.

1 reference

12 December 2020

Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial

1 reference

12 December 2020

Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human organic anion transporter 3, organic anion transporting polypeptide 4C1, and multidrug resistance P-glycoprotein.

1 reference

12 December 2020

Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide

1 reference

12 December 2020

Reaching HbA1c goals with saxagliptin in combination with other oral antidiabetic drugs

1 reference

12 December 2020

Effect of linagliptin (BI 1356) on the steady-state pharmacokinetics of simvastatin

1 reference

12 December 2020

1 reference

12 December 2020

The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans

1 reference

12 December 2020

Evaluation of the potential for steady-state pharmacokinetic interaction between vildagliptin and simvastatin in healthy subjects

1 reference

12 December 2020

Clinical pharmacokinetics of metformin

1 reference

12 December 2020

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.

1 reference

12 December 2020

Pharmacokinetics of dipeptidylpeptidase-4 inhibitors

1 reference

12 December 2020

Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes.

1 reference

12 December 2020

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.

1 reference

12 December 2020

Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema

1 reference

12 December 2020

Antihyperglycaemic agents. Drug interactions of clinical importance

1 reference

12 December 2020

Linagliptin, a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes

1 reference

12 December 2020

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

1 reference

12 December 2020

Multiple-dose administration of sitagliptin, a dipeptidyl peptidase-4 inhibitor, does not alter the single-dose pharmacokinetics of rosiglitazone in healthy subjects

1 reference

12 December 2020

Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects.

1 reference

12 December 2020

Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial.

1 reference

12 December 2020

Pharmacokinetic interactions with thiazolidinediones

1 reference

12 December 2020

Study of the pharmacokinetic interaction of vildagliptin and metformin in patients with type 2 diabetes

1 reference

12 December 2020

Bioequivalence of vildagliptin/metformin fixed-dose combination tablets and a free combination of vildagliptin and metformin in healthy subjects

1 reference

12 December 2020

Alogliptin: a new, highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes

1 reference

12 December 2020

Standards of medical care in diabetes--2010.

1 reference

12 December 2020

Sitagliptin phosphate: a DPP-4 inhibitor for the treatment of type 2 diabetes mellitus

1 reference

12 December 2020

Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes.

1 reference

12 December 2020

Rhabdomyolysis caused by a potential sitagliptin-lovastatin interaction

1 reference

12 December 2020

Janumet: a combination product suitable for use in patients with Type 2 diabetes

1 reference

12 December 2020

Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea

1 reference

12 December 2020

Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes

1 reference

12 December 2020

Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus

1 reference

12 December 2020

Oral antidiabetic drug metabolism: pharmacogenomics and drug interactions

1 reference

12 December 2020

Sitagliptin, an dipeptidyl peptidase-4 inhibitor, does not alter the pharmacokinetics of the sulphonylurea, glyburide, in healthy subjects

1 reference

12 December 2020

Effect of sitagliptin on the pharmacokinetics of simvastatin

1 reference

12 December 2020

Drug Interactions of Clinical Importance with Antihyperglycaemic Agents : An Update

1 reference

12 December 2020

Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes

1 reference

12 December 2020

10.2165/11532980-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

23 August 2017

1031488124

0 references

1 reference